Toby Maher, MD, PhD.PULMONOLOGY SCIENTIFIC ADVISORY BOARD
Clinician Scientist, Pulmonologist and Honorary Senior Lecturer, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, UK
Dr. Toby Maher is a National Institute for Health Research (NIHR) Clinician Scientist and Honorary Senior Lecturer, National Heart and Lung Institute, Imperial College, London. He is also Consultant Pulmonologist on the Interstitial Lung Disease Unit, Royal Brompton Hospital. Dr. Maher qualified from Southampton Medical School. He trained in Respiratory Medicine at the Royal Brompton Hospital and on the Transplant Unit at Harefield Hospital. During his training he gained an MSc in Respiratory Medicine from Imperial College London and undertook a Wellcome Trust funded PhD Fellowship at University College London where he investigated the role of eicosanoids in the regulation of fibroblast and airway epithelial cell apoptosis in idiopathic pulmonary fibrosis.
Dr. Maher has a subspecialty clinical interest in interstitial lung disease. He is actively involved in clinical service and his particular areas of expertise include; idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis and connective tissue disease associated interstitial lung disease.
Dr. Maher runs an active clinical and translational research program and oversees a team of 14 trial staff, PhD fellows and post-doctoral scientists. Dr. Maher’s research interests include; basic and translational research into idiopathic pulmonary fibrosis; with a major focus on biomarker discovery, early phase clinical trial design and delivery and pre-clinical validation target and compound validation. Dr. Maher’s current funded research includes; 1) the PROFILE study, a longitudinal biomarker discovery program. In collaboration with Nottingham University the PROFILE study has now recruited over 575 individuals with IPF. 2) an MRC EME funded randomized controlled trial of Rituximab as a treatment for connective tissue disease associated interstitial lung disease – the RECITAL study and 3) an NIHR Clinician Scientist fellowship to evaluate diagnostic, theragnostic and stratification biomarkers for fibrotic interstitial lung disease.
Dr. Maher is the lead consultant for clinical trials in the Royal Brompton Interstitial Lung Disease Unit. He is currently the UK principal investigator for a number of commercial studies of novel compounds being tested in trials for IPF and other interstitial lung diseases. Dr. Maher works closely with scientists at the Centre for Inflammation and Tissue Repair, University College London and has active collaborations with Nottingham University, University of East Anglia, National Jewish Hospital, Denver, US and McMaster University, Canada.
As well as publishing over 100 original research papers, expert reviews and book chapters, Dr. Maher is a senior associate editor for the journal Respirology, is an associate editor for PLOSOne and is on the editorial boards of the European Respiratory Journal, the European Respiratory Review and F1000 Journal.